Allied Corp.
ALID
$0.021
$0.000.00%
| Weiss Ratings | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.89 | |||
| Price History | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 5.00% | |||
| 30-Day Total Return | -39.66% | |||
| 60-Day Total Return | -36.75% | |||
| 90-Day Total Return | -58.00% | |||
| Year to Date Total Return | -38.24% | |||
| 1-Year Total Return | -65.00% | |||
| 2-Year Total Return | -93.00% | |||
| 3-Year Total Return | -98.70% | |||
| 5-Year Total Return | -98.65% | |||
| 52-Week High % Change | -89.81% | |||
| 52-Week Low % Change | 25.75% | |||
| Price | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.21 | |||
| 52-Week Low Price | $0.02 | |||
| 52-Week Low Price (Date) | Feb 04, 2025 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.43M | |||
| Enterprise Value | 8.94M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | -65.30% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 23.33 | |||
| Price/Book (Q) | -0.32 | |||
| Enterprise Value/Revenue (TTM) | 85.30 | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | -3.60 | |||
| Enterprise Value/EBIT | -3.36 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.44M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 877-255-4337 | |||
| Address | 460 Doyle Ave Kelowna, BC V1Y OC2 | |||
| Website | allied.health | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,540.83% | |||
| Profit Margin | -3,740.26% | |||
| Management Effectiveness | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -84.07% | |||
| Return on Equity | -- | |||
| Income Statement | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 104.80K | |||
| Total Revenue (TTM) | 104.80K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -326.50K | |||
| EBITDA (TTM) | -2.48M | |||
| EBIT (TTM) | -2.66M | |||
| Net Income (TTM) | -3.92M | |||
| Net Income Avl. to Common (TTM) | -3.92M | |||
| Total Revenue Growth (Q YOY) | 45.79% | |||
| Earnings Growth (Q YOY) | 6.74% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 14.81% | |||
| Balance Sheet | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 195.40K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 612.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -7.64M | |||
| Current Ratio (Q) | 0.065 | |||
| Book Value Per Share (Q) | -$0.07 | |||
| Total Assets (Q) | 1.95M | |||
| Total Current Liabilities (Q) | 9.49M | |||
| Total Debt (Q) | 6.71M | |||
| Total Liabilities (Q) | 9.59M | |||
| Total Common Equity (Q) | -7.64M | |||
| Cash Flow | ALID - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -47.20K | |||
| Cash from Financing (TTM) | 2.19M | |||
| Net Change in Cash (TTM) | 155.70K | |||
| Levered Free Cash Flow (TTM) | -2.43M | |||
| Cash from Operations (TTM) | -2.04M | |||
